Edgewise EDG-7500 Shows Promising Heart Disease Trial Results
Edgewise Therapeutics (EWTX) shares positive safety data from EDG-7500 trial for hypertrophic cardiomyopathy, showing no heart function decline with comprehensive results expected in Q2 2026.
Already have an account? Sign in.